Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $12.5152W HIGH $24.27
Volume
990.40 K
Value Traded
19.00 M
Short % Float
26.9%
-10.41%Week
-26.25%1 Month
-30.09%3 Month
-1.68%6 Month
-99.79%5 Year
-99.89%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
720.25 M
EPS (TTM)
-1.87
P/E Ratio
-
Ent. Value
319.97 M
Total Shares
53.64 M
Float Shares
48.06 M
Insiders
10.39%
Institutions
124.91%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
AVTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Avalo Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Avalo Therapeutics, Inc.
416Total events
8Upcoming
127Tier-1 (high impact)
2016 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutabdakibartClinical Data
Positive topline data reported for abdakibart in Phase 2 HS trial
hidradenitis suppurativasource ↗
▲Topline ReadoutabdakibartClinical Data
Positive topline data reported for abdakibart in Phase 2 HS trial
hidradenitis suppurativasource ↗
▲Topline ReadoutabdakibartClinical Data
Positive topline data reported for abdakibart in Phase 2 HS trial
hidradenitis suppurativasource ↗
▲Topline ReadoutabdakibartClinical Data
Positive Phase 2 LOTUS topline results for abdakibart in HS
hidradenitis suppurativasource ↗
●Equity OfferingCorporate
Inducement grant of option to purchase 34,000 shares to new employee
▼Equity OfferingCorporate
Completed underwritten public offering for gross proceeds of $431.3 million
▲Topline ReadoutabdakibartClinical Data
Positive topline Phase 2 LOTUS results for abdakibart in moderate to severe HS
hidradenitis suppurativasource ↗
▲Primary Endpoint MetabdakibartClinical Data
Phase 2 LOTUS trial met primary endpoint HiSCR75 at both doses
hidradenitis suppurativasource ↗
▲Partnership / LicenseCorporate
Milestone Buyout Option and Amendment Agreement related to AlmataBio acquisition
◆Topline ReadoutabdakibartClinical Data
Topline data from Phase 2 LOTUS trial of abdakibart (AVTX-009) for hidradenitis suppurativa
hidradenitis suppurativasource ↗
◆Topline ReadoutAVTX-009Clinical Data
Topline data readout from LOTUS Phase 2 trial of AVTX-009 in hidradenitis suppurativa
hidradenitis suppurativasource ↗
▲Topline ReadoutabdakibartClinical Data
Positive topline Phase 2 LOTUS results for abdakibart in HS
hidradenitis suppurativasource ↗
▲Milestone PaymentabdakibartCorporate
Recognized $10.0 million development milestone for abdakibart
◆Oral PresentationPresentation
Oppenheimer 36th Annual Healthcare Life Sciences Conference Fireside Chat
◆Oral PresentationPresentation
Guggenheim Emerging Outlook: Biotech Summit 2026 Fireside Chat
▲Enrollment CompleteAVTX-009Trial
Phase 2 LOTUS trial enrollment completed
hidradenitis suppurativasource ↗
▲Quarterly UpdateCorporate
Cash runway guidance: cash, cash equivalents and short-term investments of $98.3M as of Dec 31, 2025 expected to fund operations into 2028
▲Enrollment CompleteAVTX-009Trial
Phase 2 LOTUS trial enrollment completed
hidradenitis suppurativasource ↗
◆Enrollment CompleteAVTX-009Trial
Enrollment completion expected by year end 2025
hidradenitis suppurativasource ↗
◆Oral PresentationPresentation
Guggenheim Second Annual Healthcare Innovation Conference Fireside Chat
▲Enrollment CompleteAVTX-009Trial
Enrollment completed for LOTUS Phase 2 trial
hidradenitis suppurativasource ↗
▲Enrollment CompleteAVTX-009Trial
Enrollment completed in Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa
hidradenitis suppurativasource ↗
▲Enrollment UpdateAVTX-009Trial
Enrolled over three-quarters of planned patients in LOTUS trial
hidradenitis suppurativasource ↗
Past FDA Catalysts and PDUFA Decisions
How AVTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | Abdakibart (ABD) | Phase 2 data presentation | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C45 / 100
Pipeline Score
$96M
Pipeline Value
Richly Valued
Valuation Signal
5
Drugs Scored
0.1x
rNPV / MCap
Top 27%
Micro Cap(rank 178 of 658)
Percentile Rank
Avalo Therapeutics, Inc. carries a moderate pipeline score (45/100), with $1.2B risk-adjusted pipeline value, led by AEVI-007 in Multiple Myeloma (Phase 1), across $93B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AEVI-007 Small moleculeCompletedNCT04671251 | Multiple Myeloma | Phase 1 | COMPLETED | 13 | Mar 30, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every AVTX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sullivan Christopher RyanOfficer (Chief Financial Officer) | Option | 12,394 52,294 held | $9.88 | 09/16/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AVTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 1 % (900 %) | 66.71 M | 3.61 M | 2,396.54% ( 3.47 M) |
AVTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AVTX ranks across every disease it competes in
Competitive Position is a premium feature
See how AVTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAVTX News
AVTXAvalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Avalo Therapeutics has announced the grant of inducement equity awards to three new employees, totaling 101,600 stock options. The options, granted under Nasdaq Listing Rule 5635(c)(4), have an exercise price of $15.47 per share and will vest over four years. This move aims to attract talent and align employee interests with the company's growth.
Read more →AVTX▼ -7.3%on this news
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
Avalo Therapeutics announced its participation in the EADV Congress 2026, where it will present findings on its anti-IL-1β agent, Abdakibart, for treating moderate to severe hidradenitis suppurativa. The company will deliver a late-breaker oral presentation and a poster presentation, showcasing results from the Phase 2 LOTUS trial. This event is set to take place in Vienna, Austria from September 30 to October 3, 2026.
Read more →AVTXAvalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics will participate in several upcoming investor conferences, including the Cantor Global Healthcare Conference and the Morgan Stanley Global Healthcare Conference. The company is focused on developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Their lead candidate, abdakibart, is entering a phase 3 registrational program for hidradenitis suppurativa.
Read more →AVTXAvalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
Avalo Therapeutics reported its Q2 2026 financial results, highlighting plans to initiate a Phase 3 program for abdakibart in hidradenitis suppurativa in 2027. The company also announced the advancement of AVTX-010 and appointed Ron Philip to its Board of Directors. With $472.2 million in cash, Avalo is well-positioned for future growth despite a net loss of $36.4 million this quarter.
Read more →AVTXAvalo Therapeutics to Participate in the BTIG Biotechnology Conference
Avalo Therapeutics will participate in the BTIG Biotechnology Conference on July 29, 2026. CEO Dr. Garry Neil will join a panel discussion focused on hidradenitis suppurativa. The company will also conduct one-on-one meetings with investors during the event. Avalo is advancing its lead therapeutic, abdakibart, which has shown positive results in clinical trials.
Read more →AVTXAvalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
Avalo Therapeutics will host one-on-one investor meetings at the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston. The company is dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Their lead asset, abdakibart, has shown positive results in a Phase 2 clinical trial for hidradenitis suppurativa.
Read more →AVTXAvalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
Avalo Therapeutics has announced its inclusion in the Russell 2000 and Russell 3000 indexes, effective after the close of U.S. equity markets on June 26, 2026. This addition is significant as it highlights Avalo's position in the small-cap sector and may attract more investment interest. The company focuses on developing therapeutics targeting the IL-1β pathway for inflammatory diseases.
Read more →AVTXAvalo Therapeutics Appoints Ron Philip to Board of Directors
Avalo Therapeutics has appointed Ron Philip to its Board of Directors, bringing over 30 years of biopharmaceutical experience. His expertise is expected to aid in advancing abdakibart, which recently showed positive Phase 2 results for hidradenitis suppurativa. The company is optimistic about the drug's potential as a best-in-disease treatment.
Read more →AVTXAvalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
Avalo Therapeutics announced the advancement of AVTX-010, a long-acting anti-IL-1β monoclonal antibody aimed at treating hidradenitis suppurativa and other inflammatory disorders. The company plans to submit an IND application for AVTX-010 in the first half of 2027. This development follows positive topline data from their Phase 2 trial of abdakibart, further strengthening their pipeline.
Read more →AVTXAvalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - May 22, 2026
Avalo Therapeutics announced the grant of an inducement award of 34,000 stock options to a new employee, approved by the Compensation Committee. The award, compliant with Nasdaq Listing Rule 5635(c)(4), has an exercise price of $16.60 per share and will vest over four years. This move is part of Avalo's ongoing commitment to developing IL-1β-based treatments for immune-mediated inflammatory diseases.
Read more →AVTXAvalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Avalo Therapeutics has granted an inducement award of stock options to a new employee, totaling 34,000 shares. This grant, approved under Nasdaq Listing Rule 5635(c)(4), is part of Avalo's strategy to incentivize talent. The options will vest over four years, beginning after one year of employment. Avalo is focused on developing IL-1β-based treatments for inflammatory diseases.
Read more →AVTXAvalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Avalo Therapeutics reported positive topline results from its Phase 2 LOTUS trial for abdakibart in treating moderate to severe hidradenitis suppurativa. The trial met its primary endpoint, showing significant clinical improvement. The company also completed a public offering, raising $431.3 million to support its advancement into a Phase 3 program. Despite these successes, Avalo reported an increased net loss for the quarter.
Read more →AVTX▲ +34.1%on this news
Avalo Therapeutics Announces Pricing of $375 Million Public Offering
Avalo Therapeutics has announced the pricing of a public offering totaling $375 million, involving 19,730,000 shares of common stock and 1,400,000 pre-funded warrants. The offering is expected to close on May 7, 2026, pending customary conditions. Proceeds will be used to advance the clinical development of abdakibart and for general corporate purposes.
Read more →AVTX▲ +18%on this news· ran to +58% by day 1shared move
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
Avalo Therapeutics announced positive topline results from its Phase 2 LOTUS trial for abdakibart in treating moderate to severe hidradenitis suppurativa. The trial met its primary endpoint with significant response rates at both tested doses. Abdakibart was well tolerated, and the company plans to move forward with a phase 3 program based on these results.
Read more →AVTX▲ +18%on this news· ran to +58% by day 1shared move
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Avalo Therapeutics has initiated a public offering of common stock and pre-funded warrants. The proceeds will support the clinical development of abdakibart, particularly its Phase 3 topline data release. The offering is subject to market conditions, and the company has granted underwriters a 30-day option for additional shares. Recent positive data from a Phase 2 trial adds to the company's prospects.
Read more →AVTX▼ -10.8%on this news
Avalo Therapeutics Purchases Optional Milestone Buyout
Avalo Therapeutics has announced a Milestone Buyout Option Agreement related to its acquisition of AlmataBio. The agreement allows Avalo to pay $2.25 million for an option to pay an additional $5.125 million instead of a previously disclosed $15 million milestone payment. This move is part of Avalo's strategy to develop IL-1β-based treatments for immune-mediated inflammatory diseases.
Read more →AVTXAvalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
Avalo Therapeutics reported its 2025 financial results, highlighting a significant cash reserve of approximately $98 million, which is expected to sustain operations until 2028. The company anticipates topline data from its Phase 2 LOTUS trial for abdakibart (AVTX-009) in treating hidradenitis suppurativa in the second quarter of 2026. However, the company also faced a notable increase in net loss and research expenses compared to the previous year.
Read more →About Avalo Therapeutics, Inc.
Headquarters1500 LIBERTY RIDGE DRIVE, WAYNE, PA, 19087
Founded2011
BIOPHARMAWATCH ELITE PLUS
Trade the next AVTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime